Mestag Therapeutics, a biotech company harnessing new insights into fibroblast-immune interactions, announced that it has entered into a license and collaboration agreement with Merck & Co., Inc., Rahway, N.J., USA to identify novel targets for the development of therapies against inflammatory diseases. Mestag will employ its Reversing Activated Fibroblast Technology (RAFT) platform to identify novel drug targets. Merck & Co., Inc., Rahway, N.J., USA has the option to license one or more targets and will be responsible for the discovery, development and commercialization of resulting therapeutics.